

Global spotlight 23.1: Key additions for the first half of November 2022



There is one newly added evidence synthesis in the public-health measures part of the COVID-END inventory of ‘best’ evidence syntheses*, and one newly added synthesis in the clinical management parts of the inventory.

**COVID-END assigns ‘best’ status to evidence syntheses based on an assessment of how up-to-date they are (i.e., the date of the last search, with priority given to living reviews), quality (using the AMSTAR tool), and whether there is an evidence profile available (e.g., GRADE).*

Taxonomy section	Title	Type of synthesis	Criteria for best evidence synthesis		
			Date of last search	Quality (AMSTAR) rating	Evidence profile (e.g., GRADE) available
Public-health measures	Barriers to COVID-19 testing include delays in the decision to seek appropriate care, challenges reaching a testing facility, and not receiving adequate care when a clear diagnosis is reached or clinical manifestation is observed [Review of studies of unknown quality]	Newly added rapid review	2021-01-08	5/9	No
Clinical management of COVID-19 and pandemic-related health issues	[Mesenchymal stromal cells] Using mesenchymal stromal cells may be effective to treat COVID-19 without increasing adverse events [Review of studies with variable quality and important heterogeneity for some of its outcomes]	Newly added living review	2022-03-30	8/11	No